Brief: Biocryst Announces Positive Results Orladeyo® In Pediatric Patients With Hereditary Angioedema
24/02/2025 11:37
Feb 24 (Reuters) - BioCryst Pharmaceuticals Inc
BCRX.O :
* BIOCRYST ANNOUNCES POSITIVE RESULTS FROM APEX-P TRIAL FOR
ORLADEYO® (BEROTRALSTAT) IN PEDIATRIC PATIENTS WITH HEREDITARY
ANGIOEDEMA AGED 2 TO <12 YEARS
* BIOCRYST PHARMACEUTICALS INC - ORLADEYO SAFE AND WELL
TOLERATED
IN PEDIATRIC HAE TRIAL
Source text: ID:nGNXbvPjFl
Further company coverage: BCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026